The recommended dose of ROZLYTREK for adults is 600 mg once daily (3 x 200 mg per capsule = 600 mg). Take ROZLYTREK exactly as your doctor tells you to take it. Do not change your dose or stop taking ROZLYTREK unless your doctor tells you to.
Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with ROZLYTREK if you develop side effects.
If you miss a dose
If you vomit after a dose
Download helpful information about ROZLYTREK®.
Learn about organizations dedicated to educating and supporting people with cancer.
Central nervous system, which includes the brain and spinal cord.
Cancer that develops in the colon, which is the longest part of the large intestine and/or the rectum (the last several inches of the large intestine before the anus).
The disappearance of all signs of cancer, such as tumors, in response to treatment. This does not mean the cancer has been cured.
Molecules within cells that carry genetic information.
A type of gene made by joining parts of 2 different genes. Fusion genes make fusion proteins, which can be the root cause of some kinds of cancer.
long QT syndrome
A condition where the heart beats fast and irregularly. Long QT syndrome might cause a person to faint or have a seizure. In some instances, the heart can beat out of control for so long that it may cause sudden death.
papillary thyroid cancer
The most common type of thyroid cancer.
The decrease in the size and spread of tumors or extent of cancer in the body in response to a given treatment.
A molecule that is needed for your body to function properly. Proteins are the basis of body structures, like skin and hair, and other substances in your body.
A rare cancer found in the tissues of the gland that makes saliva.
A cancer that begins in the bone and soft tissue.
secretory breast cancer
A rare type of breast cancer.
Cancer of the thyroid. The thyroid is an organ at the base of the throat. It makes hormones that help control heart rate, blood pressure, body temperature, and weight.
An NTRK gene fusion tells the body to make abnormal versions of TRK, or tropomyosin receptor kinase, fusion proteins. TRK fusion proteins are a family of several proteins that normally plays an important role in the nervous system. People with NTRK fusion-positive solid tumors have an abnormal version of TRK called a TRK fusion protein.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.